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Do T-Wave Findings Really Help in Diagnosis?*Sudhir S. Kushwaha, MD, Avishay Grupper, MDSEE PAGE 2702S udden cardiac death (SCD) associated with ex-ercise in young athletes is a rare and tragicevent. These deaths are usually due to a vari-
ety of cardiac diseases, which may be structural, elec-
trical, or acquired abnormalities that are unsuspected
and may become manifest in the setting of strenuous
exercise (1). Following a number of high-proﬁle SCD
events in professional athletes, the question of ath-
letic screening for cardiovascular disorders with a
higher risk of malignant arrhythmias has been raised.
However, there are several obstacles to screening a
large population of young athletes: the low preva-
lence of underlying cardiovascular disease in this
age group; the different diagnostic criteria for each
disorder; and the imperfect speciﬁcity of the current
screening modalities that may lead to false-positive
screening study results. In addition, there remains
the question of what constitutes enough athletic ac-
tivity to potentially trigger SCD in a pre-disposed in-
dividual. These issues have a substantial impact on
the feasibility and cost-effectiveness of screening
this population.
The most common causes of SCD in young athletes
are several congenital or acquired cardiac malforma-
tions. The prevalence of these cardiovascular disor-
ders is estimated at 0.3% of the athletic population.
The single most common cause of athlete death is hy-
pertrophic cardiomyopathy, which is responsible for
approximately 40% of the cases, followed by con-
genital coronary artery anomalies in 17% of the cases
(2). Several other cardiovascular diseases, including
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In this issue of the Journal, Zaidi et al. (3) set out to
examine the accuracy of diagnostic criteria for ARVC
when applied to a group of young athletes and to
assess the overlap between physiological and patho-
logical ﬁndings in the different screening modalities.
Their study compared 2 groups of healthy young
athletes with and without physiological T-wave
inversion on a 12-lead electrocardiogram (ECG) to a
group of patients with an established diagnosis of
ARVC using several screening modalities.The question that arises is how the study results
differ from the current guidelines for screening young
athletes and how can they improve the speciﬁcity
of the screening recommendations. Both the Amer-
ican Heart Association and the European Society
of Cardiology have proposed guidelines for pre-
participation screening for young athletes (1,4) that
focus on a pre-participation history and physical ex-
amination. The majority of conditions that put an
athlete at risk of sudden death during exercise are
genetically inherited diseases, hence the importance
of family history in the screening process. In addition,
both guidelines highlight several symptoms that, if
present, require further testing: exertional chest pain
or discomfort; unexplained syncope or pre-syncope;
irregular heartbeat or palpitations; and excessive ex-
ertional dyspnea or fatigue. The current study results
correlate with these recommendations, as none of the
athletes expressed any symptoms suggestive of un-
derlying cardiovascular disorder or revealed a family
history of cardiomyopathy or premature SCD. In
contrast, most of the ARVC patients (71%) reported
signiﬁcant cardiovascular symptoms, and many of
them had familial heart disease and a history of SCD
in the family. These ﬁndings highlight the importance
of complete personal and family history as a feasible
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athletes.
The most signiﬁcant difference between these 2
screening guidelines is that the European Society of
Cardiology proposal includes a standard 12-lead ECG
as a screening modality, whereas the routine use of
the ECG is not recommended by the American Heart
Association because of considerations as to its prac-
ticality and cost-effectiveness and because of the
implications of a false-positive screening test. ECG is
a screening test with a relatively low speciﬁcity,
especially in the athletic population because of the
high frequency of ECG alterations associated with
normal physiological adaptations of the athlete’s
heart.
The European Society of Cardiology criteria for a
positive pre-participation screening ECG examination
are based on ﬁndings that are mainly diagnostic for
hypertrophic cardiomyopathy, the most prevalent
cardiovascular cause of SCD, but also include speciﬁc
ECG ﬁndings for ARVC using diagnostic criteria (5)
that include T-wave inversion in right precordial
leads. The most important result in the current study
of Zaidi et al. (3) highlights the low speciﬁcity of
this ﬁnding. Although most of the ARVC patients
demonstrated T-wave inversion on the 12-lead ECG,their distribution also included inferior and lateral
leads. In addition, when compared with healthy
athletes with T-wave inversion, there was no signif-
icant difference in the distribution and depth of
T waves. The new ﬁnding was a difference in the
preceding ST-segment, which was convex and el-
evated among most of the athletes, in contrast to the
isoelectric ST-segment observed in most ARVC pa-
tients. Moreover, almost all of the athletes with
T-wave inversion fulﬁlled possible or borderline
criteria for the diagnosis of ARVC mainly on the basis
of the ECG parameters.
These ﬁndings highlight the low speciﬁcity of the
12-lead ECG as a pre-participation screening tool in
young athletes and the need for more deﬁnite diag-
nostic criteria for use in this setting and to refer
athletes with suspected cardiac abnormalities to more
speciﬁc screening modalities in order to avoid un-
necessary exercise restriction due to false-positive
results, particularly on the basis of ECG ﬁndings of
T-wave inversion.
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